

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 48381

**Title:** Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape

**Reviewer's code:** 00049331

**Reviewer's country:** Turkey

**Science editor:** Ruo-Yu Ma

**Reviewer accepted review:** 2019-05-29 04:15

**Reviewer performed review:** 2019-05-30 02:56

**Review time:** 22 Hours

| SCIENTIFIC QUALITY                                     | LANGUAGE QUALITY   | CONCLUSION                                 | PEER-REVIEWER STATEMENTS                      |
|--|--|--|---|
| <input checked="" type="checkbox"/> Grade A: Excellent | <input checked="" type="checkbox"/> Grade A: Priority publishing | <input type="checkbox"/> Accept            | Peer-Review:                                  |
| <input type="checkbox"/> Grade B: Very good            | <input type="checkbox"/> Grade B: Minor language                 | (High priority)                            | <input checked="" type="checkbox"/> Anonymous |
| <input type="checkbox"/> Grade C: Good                 | polishing  | <input checked="" type="checkbox"/> Accept | <input type="checkbox"/> Onymous              |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade C: A great deal of                | (General priority)                         | Peer-reviewer's expertise on the              |
| <input type="checkbox"/> Grade E: Do not               | language polishing   | <input type="checkbox"/> Minor revision    | topic of the manuscript:                      |
| publish  | <input type="checkbox"/> Grade D: Rejection                      | <input type="checkbox"/> Major revision    | <input checked="" type="checkbox"/> Advanced  |
|  |  | <input type="checkbox"/> Rejection         | <input type="checkbox"/> General              |
|  |  |  | <input type="checkbox"/> No expertise         |
|  |  |  | Conflicts-of-Interest:                        |
|  |  |  | <input type="checkbox"/> Yes                  |
|  |  |  | <input checked="" type="checkbox"/> No        |

### SPECIFIC COMMENTS TO AUTHORS

With this paper, the Authors aimed to review of the efficacy and safety of the IBD therapeutic agents in the elderly population. The prevalence of IBD in the elderly patients has been steadily rising over the last few decades, thus this review gives us



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

valuable information regarding therapeutic strategy in elderly IBD patients. This review also showed that more prospective studies are required to better define the efficacy and safety of biologic treatment for elderly IBD patients. This minireview is acceptable for publication.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 48381

**Title:** Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape

**Reviewer's code:** 00505564

**Reviewer's country:** United States

**Science editor:** Ruo-Yu Ma

**Reviewer accepted review:** 2019-05-28 14:08

**Reviewer performed review:** 2019-06-03 04:49

**Review time:** 5 Days and 14 Hours

| SCIENTIFIC QUALITY                                     | LANGUAGE QUALITY   | CONCLUSION                                 | PEER-REVIEWER STATEMENTS                    |
|--|--|--|---|
| <input type="checkbox"/> Grade A: Excellent            | <input checked="" type="checkbox"/> Grade A: Priority publishing | <input type="checkbox"/> Accept            | Peer-Review:                                |
| <input checked="" type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language                 | (High priority)                            | <input type="checkbox"/> Anonymous          |
| <input type="checkbox"/> Grade C: Good                 | polishing  | <input checked="" type="checkbox"/> Accept | <input checked="" type="checkbox"/> Onymous |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade C: A great deal of                | (General priority)                         | Peer-reviewer's expertise on the            |
| <input type="checkbox"/> Grade E: Do not               | language polishing   | <input type="checkbox"/> Minor revision    | topic of the manuscript:                    |
| publish  | <input type="checkbox"/> Grade D: Rejection                      | <input type="checkbox"/> Major revision    | <input type="checkbox"/> Advanced           |
|  |  | <input type="checkbox"/> Rejection         | <input checked="" type="checkbox"/> General |
|  |  |  | <input type="checkbox"/> No expertise       |
|  |  |  | Conflicts-of-Interest:                      |
|  |  |  | <input type="checkbox"/> Yes                |
|  |  |  | <input checked="" type="checkbox"/> No      |

### SPECIFIC COMMENTS TO AUTHORS

LeBlanc et al. is a review article on the current available literature on the management of inflammatory bowel disease in the elderly patients, including biologic and biosimilar (anti-TNF agents, anti-integrin molecules, anti-interleukin 12/23) agents and IBD-related



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

surgeries. The challenge is that high-quality data remains scarce in terms of optimal management strategies in the elderly IBD population to date and that available trials have been mostly retrospective, of small sample size, likely owing to under-representation of such a population in the major randomized controlled trials. Greatly however, according to the authors, in the last five years, there has been a steady increase in the number of published trials, helping clarify the estimated benefits and toxicity of the existing IBD armamentarium. The literature show that a minority of elderly IBD patients (1-3%) were treated with biologics or biosimilars within the five years following diagnosis, whilst almost a quarter of these patients were receiving corticosteroid therapy despite its multiple toxicities. The low use of biologic and/or biosimilar agents in real-life settings likely stems from limited data suggesting lower efficacy and higher toxicity. This minireview is a good example of a well summarized paper aiming to highlight current outcome measurements as it portends the elderly IBD patient, as well as summarize the available therapeutic strategies in view of a growing body of evidence.

## **INITIAL REVIEW OF THE MANUSCRIPT**

### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-223-8242

**Fax:** +1-925-223-8243

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<https://www.wjgnet.com>

[ ] Plagiarism

[ Y ] No